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Abstract
The self-assembly of alternative conformations of normal proteins into amyloid aggregates has 
been implicated in both the acquisition of new functions and in the appearance and progression of 
disease. However, while these amyloidogenic pathways are linked to the emergence of new 
phenotypes, numerous studies have uncoupled the accumulation of aggregates from their 
biological consequences, revealing currently underappreciated complexity in the determination of 
these traits. Here, to explore the molecular basis of protein-only phenotypes, we focused on the S. 
cerevisiae Sup35/[PSI+] prion, which confers a translation termination defect and expression 
level-dependent toxicity in its amyloid form. Our studies reveal that aggregated Sup35 retains its 
normal function as a translation release factor. However, fluctuations in the composition and size 
of these complexes specifically alter the level of this aggregate-associated activity and thereby the 
severity and toxicity of the amyloid state. Thus, amyloid heterogeneity is a crucial contributor to 
protein-only phenotypes.
Introduction
Protein amyloids expand the range of phenotypes associated with a single genotype by 
serving as novel, self-replicating epigenetic determinants. In these cases, the heritable 
information is encoded by alternative protein conformations, which have the propensity to 
self-assemble into amyloid fibers. These complexes, in turn, associate with and incorporate 
other conformers of the same protein, effectively templating their refolding to the 
amyloidogenic state.1,2 Through this process, the persistence, progression and transmission 
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of a diverse array of phenotypes, ranging from neurodegenerative diseases in mammals to 
alternative gene expression states in yeast, becomes possible.1
The link between amyloid assembly and its biological consequences varies by protein, but 
two general models have emerged. In the first model, an amyloid-associated phenotype 
arises through the loss of a protein’s normal function when it is incorporated into aggregates. 
The most well-studied examples of loss-of-function amyloid phenotypes are the S. 
cerevisiae prion proteins Ure2, Swi1, Cyc8, Mot3, Sfp1, and Sup35, whose amyloid states 
phenocopy deletions or mutations in these factors.1 In the second model, an amyloid-
associated phenotype arises through the gain of a novel function when a protein is 
incorporated into aggregates. The most widely studied gain-of-function phenotype is the 
toxicity associated with mammalian proteins implicated in neurodegenerative diseases, such 
as the prion protein (PrP) in Creutzfeldt-Jakob and mad cow diseases, Aβ in Alzheimer’s 
Disease, and huntingtin in Huntington’s Disease. However, gain-of-function beneficial 
traits, such as hormone storage, biofilm formation, organelle biogenesis, and long-term 
memory are also associated with the assembly of other proteins into amyloid.1,3–5
Regardless of the model, the protein-based phenotypes were originally believed to emerge 
once the amyloid accumulated beyond the threshold required to impact normal physiology. 
However, studies in multiple systems have uncoupled amyloid accumulation from its 
phenotypic effects. In mammals, pathogenesis correlates poorly with the accumulation of 
ataxin-16 or huntingtin7 inclusions or protease-resistant PrP,8–10 hallmarks of the amyloid 
state. Modulation of chaperone expression ameliorates toxicity of polyglutamine-expanded 
proteins in Drosophila without impacting their accumulation in aggregates.11–13 And finally 
in C. elegans, depletion of the insulin/insulin-like growth factor-1 receptor DAF-2 
suppresses Aβ1–42 toxicity while promoting the accumulation of high molecular weight 
aggregates of the peptide.14 In many of these cases, the manipulations have now been shown 
to alter the amyloid assembly pathway and to either promote or deplete the accumulation of 
intermediates, implicating alternative species in the production of these organismal 
phenotypes.2,15
However, alterations to the assembly pathway could also impact the physical properties of 
the amyloid that does accumulate and thereby the phenotypic consequences of this process. 
In this previously unexplored scenario, multiple protein species would contribute to the 
observed phenotypes, and changes in assembly pathway dynamics would modulate the 
associated traits by altering the ratios of the contributing species. Here, we experimentally 
address this possibility for the yeast prion [PSI+], the amyloid form of the eukaryotic release 
factor 3 (eRF3/Sup35).16–18 In non-prion [psi−] cells, Sup35 is soluble and facilitates 
translation termination, but in prion [PSI+] cells, Sup35 is aggregated and functionally 
compromised, leading to the readthrough of stop codons.19,20 The severity and toxicity of 
the [PSI+] state were previously thought to reflect the equilibrium between aggregated, non-
functional and soluble, functionally engaged Sup35,21,22 but our studies, presented here, 
now demonstrate that Sup35 amyloid contributes to the level of translation termination 
activity in [PSI+] cells. The functional contribution of these complexes, however, is 
impacted by their composition and size, and these amyloid-associated effects are sufficient 
to explain fluctuations in the prion phenotype.
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Results
Aggregated Sup35 Interacts with Its Functional Partners
Loss-of-function mutations in Sup35 phenocopy the translation termination defect observed 
in a [PSI+] strain.23 However, the existence of gain-of-function beneficial amyloids 
indicates that amyloid assembly is not incompatible with biochemical activity and raises the 
possibility that aggregated Sup35 continues to function in its prion conformation. Several 
previous observations support this hypothesis. First, the Sup35 C-terminal GTPase domain 
remains accessible on the surface of amyloid fibers in vitro.24,25 Second, Sup35 retains the 
ability to hydrolyze GTP in its aggregated form in vitro.26 Third, proteins fused to the N-
terminal Sup35 prion-determining domain (PrD), such as green fluorescent protein (GFP) 
and luciferase, retain their activity when incorporated into Sup35 aggregates in [PSI+] 
cells,19 suggesting that conformational conversion is restricted to the domain required for 
amyloid formation. Nevertheless, Sup35 must still bind to its functional partner Sup45, the 
eukaryotic release factor 1 (eRF1), and the ribosome to facilitate translation termination,27 
and its ability to engage in these interactions could be compromised by aggregation.24
As a first step toward determining the contribution of aggregated Sup35 to termination 
activity in a [PSI+] strain, we assessed its ability to associate with Sup45 and the ribosome. 
Previous studies disagree on the whether aggregated Sup35 binds to Sup4528,29 or 
not19,30,31 in [PSI+] cells, but in these studies, binding was assessed indirectly by the prion-
dependent fractionation of Sup45 to the aggregate-containing pellet following high-speed 
centrifugation of yeast lysates. A direct assessment of Sup45 association with Sup35 
aggregates, however, is complicated by the fact that [PSI+] cells contain a mixture of both 
soluble and aggregated Sup35.19,20 To circumvent this difficulty, we developed a system to 
specifically monitor association of functional partners with Sup35 aggregates based on the 
ability of the PrD to co-aggregate with full-length Sup35.19,20,32 As expected, the Sup35 
PrD, tagged with an HA epitope (PrD-HA), associated with full-length Sup35 in a [PSI+] but 
not a [psi−] strain, as assessed by immunocapture (Fig. 1a), demonstrating the ability of this 
approach to specifically recover aggregated Sup35. Using this PrD-HA system, Sup45 was 
also specifically co-immunocaptured with PrD-HA from [PSI+] but not [psi−] lysates (Fig. 
1a). Thus, aggregated Sup35 retains its ability to associate with Sup45 in a [PSI+] strain.
Ribosomes were also specifically co-immunocaptured with PrD-HA from a [PSI+] but not a 
[psi−] lysate, as assessed by RT-PCR of rRNA (Fig. 1b), suggesting an association with 
aggregated Sup35 as well. Because ribosomes are in excess to Sup35 in vivo,33,34 we 
performed additional experiments to confirm the specificity of this interaction. Notably, 
PrD-HA immunocapture was unable to recover ribosomes in a strain whose only functional 
source of Sup35 activity was the Sup35 catalytic domain (Sup35-C), which cannot interact 
with prion aggregates (Fig. 1b, lane 6).32 However, PrD-HA immunocapture recovered 
ribosomes in the presence of full-length Sup35 (Fig. 1b, compare lanes 4 and 7 with lane 6). 
Because full-length Sup35 binds to PrD-HA only in a [PSI+] strain (Fig. 1a), the dependence 
of the PrD-HA/ribosome interaction on this protein indicates that prion aggregates interact 
with ribosomes. As a further test of this interaction, we examined the dependence of the 
PrD-HA/ribosome interaction on full-length Sup35 through biochemical fractionation on 
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sucrose gradients. Under these conditions, Sup35 fractionated to the top of the gradient from 
[psi−] lysates and to intermediate fractions from [PSI+] lysates (Fig. 1c). These migration 
patterns were not perturbed by RNase treatment (Fig. 1c), which destroyed rRNA 
(Supplementary Fig. 1), indicating that they reflect prion-dependent differences in Sup35 
assembly rather than ribosome association. In addition to these Sup35 pools, a fraction of 
Sup35 was also recovered in the pellet from both [PSI+] and [psi−] lysates (Fig. 1c). RNase 
treatment of the lysates led to the loss of pelletable Sup35 (Fig. 1c), suggesting that this 
fraction reflects ribosome-engaged Sup35. Notably, the PrD alone did not fractionate to the 
pellet, but it did so in the presence of full-length Sup35 and intact rRNA in a [PSI+] lysate 
(Fig. 1c, compare Sup35-C + PrD to Sup35 + PrD). Thus, this pelleted material contains 
prion aggregates that are likely engaged with ribosomes in vivo.
Aggregated Sup35 Functions in Translation Termination
These observations, together, indicate that aggregated Sup35 interacts with its functional 
partners in [PSI+] cells. But, do these interactions contribute to translation termination 
activity in [PSI+] cells? To begin to answer this question, we first established the 
relationship between Sup35 abundance and activity in vivo. To do so, we expressed Sup35 
from a doxycycline-repressible promoter as the sole source of the protein in a [psi−] strain 
and assessed stop-codon readthrough using a GST(UGA)DsRedNLS reporter as a function 
of Sup35 abundance.35 In this system, Sup35 activity was present in excess, as termination 
fidelity was maintained until the level of the protein fell to ~40% with increasing 
concentrations of doxycycline (Fig. 2a). Below this threshold, there was a near linear 
increase in stop-codon readthrough, consistent with a limitation in the availability of Sup35 
(Fig. 2a). In a wildtype [psi−] strain, Sup35 was fully soluble, and stop-codon readthrough 
was barely detectible (Fig. 2a). This combination of parameters placed the [psi−] state 
directly on the dose-response curve generated for Sup35 activity by doxycycline titration 
(Fig. 2a). In contrast, only ~10% of Sup35 protein was soluble in a wildtype [PSI+] strain, 
which exhibited a nearly 30-fold increase in stop-codon readthrough relative to a wildtype 
[psi−] strain (Fig. 2a). However, the level of stop-codon readthrough observed in the [PSI+] 
strain was significantly reduced in comparison with the level predicted for ~10% soluble 
Sup35 by the dose-response curve (Fig. 2a). These findings imply that aggregated Sup35 
makes an appreciable contribution to termination activity in a [PSI+] strain.
If both aggregated and soluble Sup35 do contribute to termination activity, we would expect 
that depletion of Sup35 would lead to an increase in stop-codon readthrough only when the 
total functional pool of Sup35 (i.e. both aggregated and soluble forms of the protein) became 
limiting. However, if only soluble Sup35 contributed to termination activity in [PSI+] cells, 
we would predict that depletion of Sup35 would lead directly to an increase in stop-codon 
readthrough because the level of soluble Sup35 in a [PSI+] strain is already below the 
threshold for faithful termination (Fig. 2a). To test this idea, we expressed Sup35 from a 
doxycycline-repressible promoter as the sole source of the protein in a [PSI+] strain. As 
expected, addition of doxycycline led to a decrease in the steady-state level of Sup35 over 
time (Fig. 2b). Notably, this inhibition of Sup35 synthesis led to a parallel decrease in both 
the soluble and aggregated pools of Sup35, indicating that the equilibrium between the two 
forms of the protein was not perturbed (Fig. 2b). Upon depletion of Sup35, stop-codon 
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readthrough increased beyond the level observed in a [PSI+] strain, but an appreciable 
increase was only observed after 1.5 generations (Fig. 2c). During this time, approximately 
50% of Sup35 was depleted (Fig. 2b), which was consistent with the threshold for the 
increase in stop-codon readthrough that we determined in a [psi−] strain (Fig. 2a). Thus, 
aggregated Sup35 must contribute to termination activity in a [PSI+] strain.
As a complementary approach, we also assessed strain viability upon Sup35 depletion, as 
the activity of this protein is essential.23 If soluble Sup35 was the only active form of the 
protein, we would predict viability to be lost earlier following the depletion of Sup35 in a 
[PSI+] strain, which accumulates only ~10% soluble Sup35 at steady state (Fig. 2a), than in 
a [psi−] strain, where Sup35 is fully soluble (Fig. 2a). To test this possibility, we expressed 
Sup35 from the cell type-specific promoters PMFA1 and PMFα1 in MATa and MATα strains, 
respectively, and mated these strains together to repress new Sup35 synthesis.35 We then 
determined the number of generations supported by the existing pool of Sup35 in [PSI+] and 
[psi−] strains by microscopy. Using this system, a [psi−] strain persisted for an average of 
seven generations after repression of Sup35 synthesis. Remarkably, the viability of the 
[PSI+] strain was similar (Fig. 2d), consistent with our observations that aggregated protein 
must contribute to the overall level of Sup35 activity in [PSI+] cells (Fig. 2a, c). If this 
scenario is indeed the case, conditions that reduce the transmission of Sup35 aggregates to 
daughter cells, such as treatment with a low level of guanidine HCl (GdnHCl),36,37 should 
strongly compromise viability of the [PSI+] strain by promoting the more rapid depletion of 
the existing protein. For the [psi−] strain, viability was reduced to an average of five 
generations in the presence of GdnHCl, presumably reflecting the mild toxicity of the 
treatment (Fig. 2d).38 However, viability was more severely reduced to an average of 3.5 
generations in the [PSI+] strain upon GdnHCl treatment, consistent with a role for 
aggregated protein in the overall level of Sup35 activity in a [PSI+] strain.
[PSI+] Toxicity Does Not Correlate with Soluble Sup35 Loss
How does this discovery of aggregate-associated activity impact our mechanistic 
understanding of the [PSI+] phenotype? To address this question, we considered prion 
toxicity. Under normal laboratory growth conditions, some [PSI+] isolates are not 
detrimental to yeast,39,40 but these isolates become toxic upon overexpression of either the 
PrD or full-length Sup35.22,31,41–43 This toxicity has been linked to the availability of either 
Sup35 or Sup45, respectively.31 In the case of PrD overexpression, a previous study 
proposed that toxicity resulted from the depletion of the small soluble pool of full-length 
Sup35 in a [PSI+] strain through its incorporation into aggregates by mass action.31 
However, the creation of new templates to accept this soluble protein is dependent on the 
activity of the molecular chaperone Hsp104 and its co-chaperones Hsp70 (Ssa1/2) and Sis1, 
which together fragment larger aggregates into smaller complexes.1 This limitation, based 
on chaperone availability, may restrict the predicted shift in equilibrium toward the 
aggregate state.44
To resolve the mechanism of toxicity associated with Sup35 overexpression in a [PSI+] 
strain, we first determined the effect of PrD overexpression on the level of soluble full-
length Sup35. Integration of a plasmid expressing the PrD ~1.3-fold (Supplementary Fig. 2) 
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into a [PSI+] strain did not reduce the level of soluble full-length Sup35 in comparison with 
the parent strain (Fig. 3a). To assess the effects of high-copy overexpression of the PrD on 
the accumulation of soluble Sup35, we constructed a [PSI+] yeast strain expressing full-
length Sup35 from its own promoter and Sup35-C from a doxycycline-repressible promoter. 
Sup35-C lacks the PrD, is incapable of incorporating into prion aggregates and suppresses 
the toxicity of overexpressed PrD.38,39 We then transformed this strain with a PrD-encoding 
high-copy plasmid, which leads to ~10-fold overexpression of the PrD on medium lacking 
uracil or ~100-fold overexpression of the PrD on medium lacking leucine.31 On medium 
lacking uracil, the levels of soluble full-length Sup35 decreased only ~2-fold relative to a 
vector control (Fig. 3b). This modest decrease was similar on medium lacking leucine 
despite the 10-fold increase in Sup35 expression relative to the medium lacking uracil (Fig. 
3b). Thus, the equilibrium between soluble and aggregated protein is limited by factors 
beyond Sup35 concentration.
Exploiting the different effects of these three levels of PrD expression, we next determined 
the relationship between the availability of soluble, full-length Sup35 and prion phenotypes 
by assessing stop codon readthrough and toxicity in these strains. For the high-copy 
condition, doxycycline was added to the growth medium to repress expression of Sup35-C 
and allow detection of these phenotypes. Although only high-copy PrD expression affected 
the level of soluble full-length Sup35 (Fig. 3a, b), both single (Fig. 3c) and high-copy (Fig. 
3d) overexpression (assessed on medium lacking uracil) of the PrD led to an increase in 
stop-codon readthrough. In the case of toxicity, growth impairment was only observed with 
the highest level of PrD overexpression attained in medium lacking leucine (Fig. 3e), 
although growth on medium lacking either uracil or leucine led to a similar reduction in the 
accumulation of soluble full-length Sup35 (Fig. 3b). Thus, these observations reveal 
additional discordance between Sup35 solubility and activity in a [PSI+] strain and, together 
with the finding that Sup35 aggregates contribute to the overall level of termination activity 
in a [PSI+] strain (Fig. 2a), indicate that previously unanticipated factors contribute to the 
severity of prion phenotypes.
Sup35 Aggregate Composition and Size Impacts Activity
What molecular events might explain these disconnects between Sup35 solubility and 
activity? In addition to the modest changes in the accumulation of soluble Sup35 that we 
observed upon PrD overexpression, increasing the synthesis rate of the prion protein will 
also increase the size of aggregates, due to the chaperone-limited fragmentation reaction.44 
This increase in aggregate size could also impact the contribution that Sup35 aggregates 
make to the overall level of translation termination activity in [PSI+] cells. Our first 
indication that this hypothesis might be valid was the disparate behavior of PrD expression 
from that of mild overexpression of full-length Sup35 in a wildtype [PSI+] strain. Notably, 
modest (~1.5-fold, Supplementary Fig. 2) overexpression of full-length Sup35 from a 
doxycycline-repressible promoter did not lead to the increase in stop codon readthrough 
observed in cells expressing a similar level of the PrD (Fig. 3c). Given the fact that neither 
condition perturbed the equilibrium between soluble and aggregated full-length Sup35 (Fig. 
3a), the most parsimonious interpretation of this observation is that the incorporation of the 
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PrD into aggregates of full-length Sup35 diminishes their activities by altering their 
composition.
To further explore the possibility that overexpression of the PrD reduces aggregate activity, 
we next assessed their ribosome engagement in the presence of high-copy PrD. Lysates from 
strains expressing different amounts of the PrD, as well as from control strains, were 
fractionated on sucrose gradients, and the amount of full-length Sup35 in the ribosome-
containing pellet was determined. Similar amounts of pelleted Sup35 were observed in 
lysates regardless of whether these cells overexpressed the PrD by ~10-fold or not (Fig. 4a, -
Ura). In contrast, the partitioning of Sup35 to the pellet was reduced ~4-fold when lysates 
from cells over-expressing the PrD by ~100-fold were analyzed (Fig. 4a, -Leu). Because 
only the strong over-expression of the PrD is toxic to cells (Fig. 3e), these results indicate 
that prion toxicity correlates with a depletion of ribosome-engaged, aggregated Sup35.
PrD overexpression, like that of full-length Sup35, is also predicted to increase the size of 
Sup35 aggregates in vivo due to the enzyme limitation of the fragmentation reaction.44 In 
vivo, Sup35 aggregates are composed of SDS-resistant polymers that assemble together into 
a larger native complex, which scales with the size of the polymers.45 With a single extra 
copy of the PrD expressed from the SUP35 promoter, the migration of aggregates on semi-
denaturing detergent agarose gels, which preserve the core polymers but not native 
aggregates, was similar to those isolated from a wildtype strain (Supplementary Fig. 3), 
suggesting that the increase in stop-codon readthrough associated with this level of PrD 
expression results from a change in aggregate composition rather than size. However, PrD 
overexpression from the high-copy plasmid had strong effects on Sup35 aggregate size in a 
[PSI+] strain. When PrD overexpression was induced ~10-fold by growth in medium lacking 
uracil, some SDS-resistant aggregates remained in the range observed in lysates from the 
vector control strain (Fig. 4b). However, these species were completely depleted in lysates 
from cells grown in medium lacking leucine in which the PrD is overexpressed by ~100-fold 
(Fig. 4b) Thus, toxicity correlates with both the depletion of ribosome-engaged Sup35 
aggregates and an increase in aggregate size.
To separate the contributions of aggregate composition and size to their activity in vivo, we 
took advantage of the fact that Sup35 assembles into aggregates of different sizes based on 
its conformation and the state of cellular proteostasis. For example, Sup35 can adopt a 
spectrum of conformations that lead to distinct phenotypic states, characterized by the level 
of stop-codon readthrough.22,46 Conformations associated with a “weak” phenotype 
assemble into aggregates of higher thermodynamic stability, increased size and decreased 
transmissibility relative to conformations associated with a “strong” phenotype (Fig. 
5a).21,44,45 Moreover, deletion of the N-terminal acetyltransferase NatA reduces the size of 
Sup35 aggregates (Fig. 5a) without altering the equilibrium between aggregated and soluble 
protein through a complex pathway,47 and these changes result in a reversal of the 
translation termination defect in [PSI+] cells.47,48 Using this panel of strains expressing a 
single copy of PrD-HA, we correlated Sup35 aggregate size with translation termination 
activity and ribosome association.
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Taking into account differences in the equilibrium between aggregated and soluble Sup35 
using our dose-response curve (Fig. 2a), we observed an inverse correlation between 
aggregate size and activity in translation termination. For the [PSI+]Strong strain, which 
accumulated Sup35 aggregates of intermediate size (Fig. 5a), we observed an intermediate 
level of aggregate-associated translation termination activity (Fig. 5b). Relative to the 
[PSI+]Strong strain, the increased Sup35 aggregate size observed in a [PSI+]Weak strain 
correlated with a decrease in aggregate-associated activity, and the decreased Sup35 
aggregate size observed in a [PSI+]Strong ΔNatA strain correlated with an increase in 
aggregate-associated activity (Fig. 5b). Following immunocapture of PrD-HA and analysis 
of rRNA by RT-PCR, we also noted an inverse correlation with size. The intermediate size 
aggregates isolated from the [PSI+]Strong strain captured an intermediate level of ribosomes; 
the larger aggregates isolated from the [PSI+]Weak strain captured a lower level of 
ribosomes, and the smaller aggregates isolated from the [PSI+]Strong ΔNatA strain captured a 
higher level of ribosomes (Fig. 5c). Thus, beyond changes in aggregate composition, our 
observations indicate that smaller Sup35 aggregates engage the ribosome more efficiently 
and contribute more termination activity to the cell than their larger counterparts.
To develop a more quantitative relationship between Sup35 aggregate size and activity, we 
took advantage of our previously developed mathematical model of prion propagation.44 
Our previous studies accurately captured the [PSI+]Strong and [PSI+]Weak states, and we used 
the same model but with a 3-fold increase in the [PSI+]Strong fragmentation rate to capture 
the [PSI+]Strong ΔNatA state, which has an increased accumulation of Hsp104.47 Using these 
parameters, we numerically generated aggregate size distributions for the three strains (Fig. 
6a), and these outputs accurately recapitulate our experimental observations (Fig. 5a). Using 
these distributions, we explored three models to explain the activity of Sup35 aggregates 
relative to their size in a [PSI+] strain: 1) a linear increase in activity with size, 2) no change 
in activity with size, and 3) a power decrease in activity with size.
We next calculated the least squares solution that most accurately explains the empirically 
determined aggregate activities (Fig. 5b) and the dose-response curve for the corresponding 
level of soluble Sup35 present (Fig. 2a) for each of the model formulations. To compare the 
fits, we calculated the residual sum of the least squares errors for each model and the Akaike 
Information Criterion (AIC) (Table 1). AIC is a common model selection test, which 
considers both the agreement of a statistical model to a given data set and the complexity 
(number of parameters) of the model. When comparing between models, the model with the 
lowest AIC is preferred. For model 3, we explored a range of powers (β), and selected a 
solution of 0.276, the minimum of the residual sum of the least squares errors, as the 
optimum value (Supplementary Fig. 4). [Note, a linear decrease in aggregate activity with 
size is represented by the condition β = −1.] As expected based on the inverse correlation 
between aggregate size and activity that we measured empirically (Fig. 5b), the first model 
(activity increases linearly with size) has the largest residual sum of least squares errors; the 
second model (no size dependence of activity) has an intermediate residual sum of least 
squares errors, and the third model (activity decreases with size) has the lowest residual sum 
of least squares errors overall (Table 1). By comparing the ratio of the residual sum of least 
squares errors, model 3 outperforms model 2 by ~27-fold and model 1 by ~578-fold and, 
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correspondingly, exhibits the lowest AIC of the models (Table 1). Our computational 
modeling, therefore, reveals an exponential decrease in Sup35 aggregate activity with size 
(Fig. 6b) as the most robust explanation for the phenotypic variability of these states. This 
model, in contrast to the others, also uniquely explains the observed threshold effect, in 
which a 10-fold increase in expression of Sup35 converts a completely benign state into a 
strictly toxic one (Fig. 3e), by linking a modest change in aggregate size (Fig. 4b, Fig. 5a) to 
a drastic reduction in activity (Fig. 5b). Thus, amyloid heterogeneity plays an essential role 
in the determination of protein-only phenotypes.
Discussion
Loss-of-function yeast prion phenotypes are, at first glance, inconsistent with many previous 
studies that directly analyzed the effects of conformational conversion and assembly on 
enzymatic activity. For example, diverse proteins, such as GFP, luciferase, carbonic 
anhydrase III, glutathione-S-transferase (GST), and barnase retain their activities when 
fused to the PrD of either Sup3519 or another yeast prion protein Ure2 and aggregated in 
[PSI+] or [URE3] strains, respectively,49 and Ure2 retains its native glutathione peroxidase 
activity in its fibrillar form.50 However, these enzymes have either intrinsic activity or act on 
small diffusible substrates, raising the possibility that the loss-of-function prion phenotypes 
arise from steric occlusion of essential interactions in the aggregate form.24,49 Following 
from this model, the yeast prion [PSI+] was previously thought to confer a translation 
termination defect through sequestration of Sup35 into amyloid aggregates.19,20 However, 
our studies reveal that in vivo aggregated Sup35, which exhibits the SDS-resistance of in 
vitro amyloid fibers,51 retains interactions with its functional partners Sup45 and ribosomes 
(Fig. 1a, b, c), consistent with the exposure of its functional C-terminal domain on the 
surface of amyloid fibers,24,25 and contributes termination activity (Fig. 2a, c, d) in [PSI+] 
cells. Thus, the equilibrium between soluble and aggregated Sup35 is insufficient to explain 
the molecular basis of the [PSI+] phenotype in vivo.
How does this functional contribution of aggregates impact our understanding of a loss-of-
function amyloid phenotype? Within the framework of this refined model, our studies 
indicate that amyloid aggregates vary in their activities in vivo (Fig. 5a, b, 6b), and this 
heterogeneity provides a molecular explanation for previously enigmatic aspects of prion 
biology in yeast. First, deletion of the N-terminal acetyltransferase NatA reverses the [PSI+] 
phenotype without altering the accumulation of SDS-resistant Sup35 aggregates.61,62 Based 
on our studies, the smaller complexes that accumulate in this strain (Fig. 5a)47,48 have 
increased translation termination activity (Fig. 5b) and ribosome association (Fig. 5c), 
thereby uncoupling Sup35 aggregates from their normal phenotypic effects. Second, benign 
variants of [PSI+] become toxic upon overexpression of the PrD.22,31,41–43 Based on our 
observations, this toxicity arises from a decrease in termination activity upon PrD 
incorporation into aggregates of full-length Sup35 at low doses (Fig. 3c) and/or to a 
depletion of smaller, ribosome-engaged aggregates at high doses (Fig. 4a, b). Finally, our 
observations may also provide an explanation for the synthetic lethality of [PSI+] with an 
Hsp104 A503V mutant.52 While this genetic interaction could reflect a gain-of-function 
toxicity, expression of Hsp104 A503V in a [PSI+] strain increases Sup35 aggregate size, 
which will decrease the contribution of these complexes to termination activity according to 
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our observations (Fig. 5b). Consistent with this interpretation, the toxicity of Hsp104 A503V 
in a [PSI+] strain is suppressed by Sup35-C, suggesting it reflects a Sup35 limitation rather 
than a gain-of-function phenotype.52 Thus, variation in the composition and size of SDS-
resistant Sup35 aggregates, which impact the engagement of these complexes with its 
functional partners perhaps through changes in their diffusional properties and/or local 
concentration effects, is a previously unanticipated contributor to the severity and toxicity of 
the prion state.
In mammals, amyloid toxicity has also been uncoupled from its accumulation in many 
systems. The general model that has emerged to explain these observations is that 
intermediates, either on- or off-pathway, that arise during fibrilization are the toxic 
species.2,15,53 Significant experimental support for this toxic intermediate model has been 
collected in mice, Drosophila, C. elegans, and yeast,6–14,54 but such a model does not 
exclude potential contributions of other misfolded species, including amyloid,55 to cellular 
dysfunction.2,53,55,56 Detailed temporal studies using several amyloidogenic proteins have 
uncovered a multi-step pathway of assembly, in which unstructured oligomeric 
intermediates arise and progress to more structured protofibrils and ultimately to highly 
ordered fibers.2,51 The relative populations of these misfolded species, which are composed 
of the same protein, are interconnected and, as such, are all impacted by changes in 
experimental conditions. Each of these misfolded species will present non-native surfaces to 
the cellular environment2,56 and may vary in their functional contributions,57 as we have 
demonstrated for Sup35 amyloid. Thus, pathogenesis is more likely to reflect the combined 
effects of this fluctuating population of species, each of which may be associated with a gain 
and/or loss of function, rather than the appearance of a single toxic species.2,56
Beyond uncovering a functional contribution for aggregates in vivo, our studies highlight the 
more nuanced, and often underappreciated, role that amyloid heterogeneity plays in defining 
protein-based traits. Many amyloidogenic proteins can determine a range of phenotypes in 
vivo upon their aggregation. Especially in the case of prions, this variability is believed to 
arise from differences in the conformation of the protein,15,58,59 which impacts the 
accumulation of the assembled aggregates by altering the rate of their self-replication.21,44,60 
Our studies suggest an alternative and, in some cases, likely interconnected possibility that 
aggregate size and composition also contribute to the phenotypic variability of protein-based 
traits. Notably, amyloid size has already been linked to prion transmissibility in mammals 
and in yeast,44,60 and factors that influence the severity and toxicity of protein-based traits, 
such as overexpression of the protein and differences in the accumulation of proteolytic 
fragments,2,61 are also likely to alter the physical attributes of aggregates without necessarily 
changing protein conformation. Thus, amyloid heterogeneity may provide a new window 
through which protein misfolding disease mechanisms can be viewed.
Methods
Plasmids
All plasmids used in this study are listed in Supplementary Table 1. SB653 is derived from 
pRS305 and contains the SUP35 promoter (PSUP35) as an EcoRI/BamHI fragment followed 
by PrD-HA3 as a PstI/SalI fragment subcloned from p316SpSup-HA3-FL.62 SB782 contains 
Pezza et al. Page 10
Nat Commun. Author manuscript; available in PMC 2015 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
PSUP35-PrD-HA3 isolated as a XhoI/SacI fragment from SB653 and subcloned into the high-
copy leu2-d plasmid pEMBL-yex.32 SB736 contains the CYC1 promoter (PCYC1) as an SacI/
XbaI fragment and PrD-HA3 as an BstXI-ClaI fragment in pRS306.63 SB531 was generated 
by inserting the GPD promoter (PGPD) as a SacI/BamHI fragment, GST-UGA as a BamHI/
EcoRI fragment and DsRedNLS as a EcoRI/XhoI fragment into pRS304.63 SB581 contains 
a PrD-GFP fusion as a BamHI/SacI fragment and the SUP35 promoter as an EcoRI/BamHI 
fragment in pRS305.63 SB397 contains the SUP35 promoter as a EcoRI/BamHI fragment, 
the PrD as a BamHI/SacII fragment and GFPssrA as a SacII/SacI fragment into pRS306. 
SB515 contains the MFα1 promoter (PMFα1) as an AvaI/BamHI fragment in pFA6a–
kanMX4, and SB526 contains the MFA1 promoter (PMFA1) as a BglII/BamHI fragment in 
pFA6a–kanMX6.
Yeast Strains
All strains are derivatives of 74-D69418 and are listed in Supplementary Table 2. Yeast 
strains were constructed to ectopically express Sup35, the PrD, or the 
GST(UGA)DsRedNLS reporter from integrating plasmids (Supplementary Table 1) based 
on the vectors pRS304, pRS305, or pRS306.63 These plasmids were integrated following 
digestion with Bsu36I, PpuMI, or StuI, respectively. Protein expression was confirmed by 
immunoblotting with specific antiserum in all cases. For strains SY2059 and SY2061, the 
HA3 epitope was fused to the C-terminus of NM-GFP by transformation of a DNA fragment 
generated by PCR using pFA6a-3HA-kanMX664 as a template and primers JP87 and JP88 
(Supplementary Table 3). The promoter and the PrD of Sup35 were replaced at the 
endogenous locus with the MFA1 promoter by transformation of a PCR fragment generated 
using SB526 as a template and primers JP8 and 3PMFA1Cterm (Supplementary Table 3). 
Replacements were selected on complete media supplemented with G418 and confirmed by 
PCR. The SUP35 promoter was replaced with PtetO7 by transforming strains with a PCR-
generated fragment using pCM22565 as a template and primers TRS218 and TRS219.66 The 
SUP35 promoter was replaced with the MFα1 promoter by transforming strains with a PCR 
fragment using SB515 as a template and primers JP33 and JP34 (Supplementary Table 3). 
The SUP35 promoter was replaced with the MFA1 promoter by transforming strains with a 
PCR fragment using SB526 as a template and primers JP30 and JP8 (Supplementary Table 
3). SY2076 was generated by mating SY2070 to 74D-694 [PSI+]Weak.46 SY1170 was 
generated by mating SY1163 to SY356.48 SY2061 was generated by mating SY2050 to 
SY1170. For all matings, tetrads were dissected by micromanipulation on rich medium, and 
meiotic progeny were characterized for auxotrophies to allow selection of the appropriate 
strains.
Protein Analysis
Immunocapture was performed as previously described67 with the following changes: 25 
OD600 units of cells were harvested in early log phase; lysis buffer contained 10 mM 
MgCl2; all wash steps were performed at 4°C; lysates were precleared with Protein G 
Magnetic Beads (New England Biolabs), and immunocapture was performed with anti-HA 
high affinity rat monoclonal antibody clone 3F10 (Roche Applied Sciences) and Protein G 
Magnetic Beads (NEB). For RNA isolation, immunocaptured samples were treated with 
proteinase K at 250 µg/ml in 50 mM Tris-Cl (pH7.4), 50 mM NaCl, 5 mM EDTA, 0.5% 
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SDS at 42°C for 1 hour. Following proteinase K treatment, phenol:chloroform:isoamyl 
alcohol (25:24:1) extractions were performed twice followed by ethanol precipitation after 
the addition of LiCl to 800 mM. Samples were then treated with 4U Turbo DNase (Ambion) 
for 30 min at 37°C followed by phenol/chloroform extraction and ethanol precipitation with 
100 mM sodium acetate, pH 5.2. Samples were resuspended in DEPC-treated water and 
analyzed by qRT-PCR using SYBR Green One-Step qRT-PCR Kit with ROX (Invitrogen) 
with 2 mM MgSO4 and primers JP53 and JP54 for 18S rRNA amplification or JP55 and 
JP56 for 26S rRNA amplification. Dissociation curves generated a single peak for all qPCR 
reactions. For sucrose gradient fractionation, lysates were prepared by glass-bead disruption 
at 4°C in lysis buffer [40 mM Tris-HCl (pH 7.4), 150 mM KCl, 15 mM MgCl2, complete 
protease inhibitor tablet (Roche Applied Sciences) and 20 U/ml rRNAsin (Promega)]; 
rRNAsin was not included in samples to be treated with RNase. Glass beads were separated, 
and the lysate was precleared for 3 minutes at 5900 × g at 4°C. 100 µl of the supernatant 
(200 µg total protein content) was loaded to the top of a 2 ml, 15–60% sucrose gradient 
made in lysis buffer and centrifuged for 3 hours at 31,000 rpm in a TLS55 swinging bucket 
rotor using an Optima Max Ultracentrifuge (Beckman). Gradients were separated into 
thirteen equal fractions by pipetting from the top of each gradient, and the pellet was 
collected. Samples were analyzed by quantitative immunoblotting with the appropriate 
antisera using standard protocols. Samples digested with RNase were incubated with 0.5 µg 
RNase (Roche) for 15 minutes at room temperature immediately prior to loading on the 
sucrose gradient. RNA visualization was performed by mixing 29 µl of each fraction to 
generate a 7% sucrose, 0.045% Orange G and 1% SDS solution. 15 µl of this mix was 
separated on 0.8 % TAE agarose gel with 0.5 µg/ml ethidium bromide. Soluble Sup35 
fractions were determined by comparing the level of Sup35 entering an SDS-PAGE gel by 
quantitative immunoblotting of lysates treated with 2% SDS at either 53°C or 100°C, as 
previously described.48 Stop-codon readthrough was determined by analysis of lysates 
isolated from strains expressing GST(UGA)DsRedNLS by quantitative immunoblotting for 
GST. Stop-codon readthrough was determined as the fraction of GST-DsRedNLS 
expression relative to total GST (GST and GST-DsRedNLS). The level of stop codon 
readthrough attributed to Sup35 aggregates was determined by quantifying the level of 
soluble Sup35 in the strain by SDS sensitivity as described above, determining the amount 
of stop codon readthrough expected for that level of soluble protein based on the dose-
response curve in Fig. 2a, and subtracting this level of stop codon readthrough from the 
actual level measured using the reporter GST(UGA)DsRedNLS as described above. Activity 
was calculated by subtracting the stop codon readthrough attributed to aggregates from 
unity, and normalizing these levels to the amount of Sup35 in aggregates. For SDD-AGE, 
cells were grown in liquid YPD, harvested, washed, and mechanically disrupted with glass 
beads in buffer (50 mM sodium phosphate pH 7.5, 100 mM NaCl, 1mM DTT, 2mM PMSF, 
and 5 µg/ml Pepstatin). Following clearing of the lysate at 500 × g for 1 minute at 4°C, 
normalized samples were separated on a 1.5% Tris-glycine agarose gel containing 
0.1%SDS, transferred to PVDF membrane, and analyzed by immunoblotting using Sup35-
specific antiserum (1:2000 dilution).
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Viability Assay
Zygotes were isolated from the indicated crosses by micromanipulation and were allow to 
divide at 30°C until growth ceased. The resulting microcolonies were disrupted using a 
micromanipulator and individual cells were counted. Generations were extrapolated by 
calculating the log base 2 of the number of cells.
Mathematical Modeling
Aggregate distributions were computed for the three prion strains using a stochastic 
simulation model previously presented.44 Parameter values for the [PSI+]Strong and 
[PSI+]Weak strains were as previously reported.44 Parameters for the ΔNatA strain were the 
same for [PSI+]Strong except the value for fragmentation was increased 3-fold to account for 
the elevation of Hsp104.47 The associated level of aggregate activity was determined for 
each strain by first determining the level of activity for the soluble fraction of Sup35. The 
activity associated with Sup35 for [psi−] strains (Fig. 2a) was fit using Mathematica’s 
FindFit function to an exponential distribution (a exp(b), a = 4.33777, b = 4.98471). Thus 
for each simulation, the activity related to the soluble Sup35 was computed using the 
exponential approximation, and the level of activity attributed to an aggregate was 
determined using three models: (1) all aggregates have equal activity (A = ∑i α2 ni), where A 
represents aggregate-associated activity, i represents the number of monomers in an 
aggregate, and nirepresents the number of aggregates of size i ), (2) the activity of an 
aggregate is proportional to the number of monomers (A = ∑i α1 i ni) (3) the activity of an 
aggregate is proportional to a power (β) of the number of monomers (A = ∑i α3 iβ ni). In all 
cases, α represents a proportionality constant between aggregate activity and size 
distribution. A least squares fit was used to determine the best fitting parameters for each 
model. Errors in our observations were assumed to be normally distributed with mean zero 
and the same variance. As such, the Akaike Information Criterion (AIC) values for each 
model could be determined with the residual sum of squared errors. In these cases AIC = n 
log(RSS/n) + 2k + C where RSS is the residual sum of squares, n is the number of data 
points, k is the number of parameters in the model and C is a constant, which does not 
contribute to the comparison between models.68
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Aggregated Sup35 associates with Sup45 and the ribosome in [PSI+] cells
a. PrD-HA expressed in haploid [PSI+] (+) or [psi] (-) yeast strains was immunocaptured 
(IC) from lysates (Ab, +) in comparison with a reaction lacking specific antiserum (Ab, -), 
and the isolated complexes were analyzed by SDS-PAGE and immunoblotting for PrD, 
Sup35 and Sup45. Total protein in the cell lysates was analyzed in parallel to ensure 
equivalent expression and extraction. b. Following PrD-HA IC as in panel (a), the presence 
of ribosomal subunits was assessed by qRT-PCR using primers specific for either 18S or 
26S ribosomal RNAs. All strains express untagged full-length Sup35 except lane 6, which 
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contains a Sup35 deletion. Lanes 6 and 7 also express the GTPase domain of Sup35 (Sup35-
C). The data represent the average of at least three independent experiments, and the error 
bars represent SEM; *p=0.013; **p≤0.004 by unpaired Student’s t-test. c. Sucrose density 
gradients were used to fractionate lysates isolated from wild-type (WT) [psi] or [PSI+] 
strains and from [PSI+] strains expressing the PrD in the presence of Sup35-C or full-length 
Sup35. The lysates were either untreated (-) or treated with RNase (+) before fractionation. 
Following centrifugation, fourteen fractions including the pellet were collected and analyzed 
by immunoblotting (IB) for Sup35 or the PrD.
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Fig. 2. Aggregated Sup35 Contributes Translation Termination Activity to [PSI+] Cells
a. The levels of soluble Sup35 relative to a wildtype [psi] strain and stop-codon readthrough 
relative to wild-type [PSI+] strain were determined in lysates from wildtype [psi] (gray 
square), wildtype [PSI+] (white triangle) and a [psi] strains expressing Sup35 from a 
doxycycline-repressible promoter (Ptet; black circles). These strains also expressed a 
reporter for stop-codon readthrough (GST(UGA)DsRedNLS). The levels of Sup35 and GST 
were determined by quantitative immunoblotting. Error bars represent STDEV; n= 6. b. The 
relative levels of soluble (black circles) and aggregated (white squares) Sup35 in a Ptet-
SUP35 [PSI+] strain were determined at the indicated generations following doxycycline-
induced repression of Sup35 synthesis by quantitative immunoblotting. Error bars represent 
SEM; n=3. c. The relative level of stop-codon readthrough of GST(UGA)DsRedNLS a Ptet-
SUP35 [PSI+] strain was determined by analysis of lysates by quantitative immunoblotting 
for GST at various times after addition of doxycycline. Error bars represent SEM; n=3. d. 
[PSI+] (gray) and [psi] (white) zygotes with repressed Sup35 synthesis were analyzed by 
microscopy to determine the number of generations supported by the existing pool of Sup35 
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in the absence (-) and presence (+) of guanidine hydrochloride (GdnHCl). Error bars 
represent SEM; n≥ 20; *p=0.0001 by unpaired Student’s t-test.
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Fig. 3. The severity and toxicity of the [PSI+] state cannot be explained by fluctuations in the 
level of soluble Sup35
a. The levels of soluble Sup35 were determined in lysates from wildtype [psi] and [PSI+] 
strains and from [PSI+] strains expressing full-length Sup35 from Ptet at ~1.5-fold the 
wildtype level (Sup35) or the PrD from PSUP35 (PrD) by quantitative immunoblotting for 
Sup35. All strains also expressed the stop-codon readthrough reporter 
GST(UGA)DsRedNLS. Error bars represent SEM; n≥3. b. Strains expressing full-length 
Sup35 from PSUP35 and Sup35-C from Ptet were transformed with either vector or a high-
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copy plasmid that over-expresses the PrD ~10-fold on medium lacking uracil (-Ura) or 
~100-fold on medium lacking leucine (-Leu). The levels of soluble Sup35 under these 
conditions were determined in lysates by quantitative immunoblotting. Error bars represent 
SEM; n≥5; *p=0.004 by unpaired Student’s t-test. c. Stop-codon readthrough was 
determined in lysates from the strains described in panel (a) by quantitative immunoblotting 
for GST. Error bars represent SEM; n≥3; *p=0.017 by unpaired Student’s t-test.. d. Stop-
codon readthrough was determined as in panel (c) in lysates from the strains described in 
panel (b). Strains were grown in medium lacking uracil (-Ura) in the presence of 
doxycycline to repress expression of Sup35-C. Error bars represent SEM; n≥3; *p=0.01 by 
unpaired Student’s t-test.. The differences in levels of stop codon readthrough in panels (c) 
and (d) represent the different baselines in rich (c) and minimal (d) medium. e. The strains 
described in panel (b) were plated on medium lacking uracil (-Ura) or lacking leucine (-Leu) 
in the absence (-) or presence (+) of doxycycline to repress Sup35-C expression and assess 
toxicity of overexpressed Sup35.
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Fig. 4. The toxicity associated with PrD overexpression correlates with a depletion of a subclass 
of Sup35 aggregates
a. Lysates from [PSI+] strains overexpressing the PrD as described in Fig. 3b that were 
grown in medium lacking either uracil (-Ura) or leucine (-Leu) were fractionated on sucrose 
gradients and analyzed by quantitative immunoblotting for Sup35 as described for Fig. 1c. 
The percentage of Sup35 in the pellet was determined relative to the total amount of Sup35 
distributed across the gradient. Error bars represent SEM; n≥5; *p=0.017 by unpaired 
Student’s t-test.. b. Lysates from strains described in panel (a) were grown in medium 
lacking uracil (-Ura) or leucine (-Leu) and were analyzed by SDD-AGE and 
immunoblotting for Sup35. Lysates were normalized for Sup35 expression prior to loading 
to allow comparisons of aggregate size.
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Fig. 5. Sup35 aggregate size correlates inversely with aggregate activity and association with 
ribosomes
a. Lysates from [PSI+]Strong, [PSI+]Weak and [PSI+] ΔNatA strains, each expressing PrD and 
GST(UGA)DsRedNLS, were analyzed by SDD-AGE and immunoblotting for Sup35. b. 
Termination activity attributed to aggregates was determined in lysates isolated from the 
strains described in panel (a) by quantitative immunoblotting for GST. Error bars represent 
SEM; n=3; *p=0.0031 and **p=0.0012 by unpaired Student’s t-test. c. Lysates isolated from 
the strains described in panel (a) were immunocaptured as described in Fig. 1b for 18S 
ribosomal RNA. Error bars represent SEM; n=3; *p =0.001 and **p=0.0004 by unpaired 
Student’s t-test.
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Fig. 6. Mathematical modeling supports an inverse correlation between Sup35 aggregate size and 
activity
a. Aggregate size distributions for [PSI+]Strong (solid) [PSI+]Weak (dashed), and [PSI+] 
ΔNatA (dotted) resulting from stochastic simulations of a mathematical model for prion 
propagation. b. The relationship between aggregate activity and size corresponding to model 
3 (power decrease in activity with size) for β=0.25 (see text for details).
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Table 1
Analysis of Aggregate-Activity Models
Model ActivityDependence RSS*
RSS Ratio
(Model X/Model 3) AIC
1 Linear increase in
activity with size 0.446981 578.668617 −3.71155
2 No change in
activity with size 0.021168 27.404425 −12.8616
3 Power decrease in
activity with size 0.00077243 - −20.7937
*
residual sum of least squared errors
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